Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network
Conclusions
In this population-based study, prescriber compliance was reasonable near pazopanib initiation but low during subsequent weeks of treatment. This study provides information from real-world community practice settings and offers feedback to regulators on the effectiveness of label monitoring guidelines.
Source: Journal of Patient Safety - Category: Health Management Tags: Original Articles Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemistry | Databases & Libraries | Hepatocellular Carcinoma | Kidney Cancer | Laboratory Medicine | Liver | Liver Cancer | Netherlands Health | Renal Cell Carcinoma | Study | Urology & Nephrology | Warnings